UNSPSC 51282006: Bacitracin a

This classification denotes an antibiotic with the molecular formula C66H103N17O16S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DDA3RRX0P7, chemically known as l-asparagine, n-(((4r)-2-((1s,2s)-1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl)carbonyl)-l-leucyl-d-.alpha.-glutamyl-l-isoleucyl-l-lysyl-d-ornithyl-l-isoleucyl-d-phenylalanyl-l-histidyl-d-.alpha.-aspartyl-, (10->4)-lactam, but more generally known as bacitracin a, which bears US NIH Compound Identifier 65281.

European Medicines Agency schedules bacitracin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG. Most nations, for tariff purposes, schedule bacitracin a under HS 29419000. SMILES:. Bacitracin a bears US NLM identifiers UMLS ID C0052882 and NCI Concept Code C76238.

UNSPSC 51282006 Bacitracin a is a Commodity code capturing antibiotic ointment products procured by state and local health systems, corrections facilities, and institutional healthcare providers. State and local governments buy bacitracin under this code as a topical first-aid and wound-care staple, typically as part of broader generic pharmaceutical and over-the-counter (OTC) product contracts awarded through cooperative purchasing vehicles. The work involves supplying manufactured pharmaceutical products meeting current Good Manufacturing Practices (cGMP), FDA compliance, Drug Supply Chain Security Act (DSCSA) certification, and National Drug Code (NDC) specifications, with distribution through authorized wholesale channels and performance obligations including timely reporting, onboarding compliance, and class-of-trade adherence.

The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products including bacitracin, with a response deadline of March 26, 2026. The solicitation (S1070000015802) requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with contract awards effective July 1, 2026 and a two-year initial term. Evaluation is weighted heavily toward price competitiveness (75 percent), with smaller allocations for fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format adherence (5 percent). Vendors must maintain commercial general liability of $5,000,000 per occurrence and comply with a 3 percent administrative fee on all contract purchases, with performance penalties of $200 to $1,500 per violation.